does tirzepatide affect heart rate Effects of on circulatory overload and end-organ damage in failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Exacerbation of Postural Orthostatic Tachycardia

#CaringforLife #CiplaAt90 To view or add a comment, sign in Cipla launches Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) two of the countrys most pressing health challenges

Tuft cells express succinate receptor 1 on their surface which detects the presence of this in SCFA in the gut lumen stimulating downstream signalling pathways and leading to a type-2 IR (Nadjsombati et al

On the go: carry the bottle and dose anywhere

K.RiveroR

It is a direct-acting, cell-remodeling and gene-modulating peptide

Always check local regulations and seek professional advice